Schrödinger, Inc., along with its affiliated entities, specializes in developing and deploying a sophisticated, physics-based software platform designed to accelerate the discovery of novel molecules. This technology finds application in both pharmaceutical development and various materials science endeavors. The company's operations are divided into two primary segments: Software and Drug Discovery. Within its Software division, Schrödinger focuses on marketing and licensing its specialized software. This software primarily serves drug discovery efforts within the life sciences industry, but also caters to clients in materials science sectors. Conversely, the Drug Discovery segment is dedicated to cultivating a portfolio of both preclinical and clinical programs. These initiatives are pursued both through internal research and development and via strategic collaborations. Schrödinger's global clientele spans biopharmaceutical companies, industrial enterprises, academic institutions, and government research laboratories worldwide. Founded in 1990, the company maintains its headquarters in New York, New York.
